<DOC>
	<DOCNO>NCT02283177</DOCNO>
	<brief_summary>This pilot study design evaluate safety tolerability oral crenolanib besylate give sequentially standard induction consolidation chemotherapy patient newly diagnose AML FLT3 activate mutation .</brief_summary>
	<brief_title>A Safety Tolerability Study Crenolanib Combination With Chemotherapy Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Crenolanib</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>1 . Unequivocal diagnosis AML base WHO classification , exclude acute promyelocytic leukemia 2 . No prior therapy AML , except hydroxyurea , set allow . 3 . Subjects AML evolve MDS may receive prior MDS therapy demethylating agent 4 . Subjects must test positive FLT3ITD and/or FLT3 activate mutation 5 . Age ≥18 year 6 . ECOG PS 0 2 7 . Adequate liver function , define normal total bilirubin , ALT ≤2.0x ULN , AST ≤2.0x ULN measure within 24 hour prior crenolanib commencement 8 . Adequate renal function , define serum creatinine ≤1.5x ULN GFR &gt; 50 mL/min 9 . Negative pregnancy test ( serum urine ) woman childbearing potential ( WOCBP ) • Women consider childbearing potential include follow : menses least 2 year menses within 2 year amenorrheic least 2 month luteinizing hormone ( LH ) follicular stimulate hormone ( FSH ) value within normal range ( accord definition postmenopausal laboratory use ) bilateral oophorectomy radiation castration amenorrheic least 3 month bilateral tubal ligation 10 . WOCBP must practice contraception . Acceptable method contraception double barrier method ( condom spermicidal jelly foam diaphragm spermicidal jelly foam ) , oral , depo provera , injectable contraceptive , intrauterine device , tubal ligation , abstention 11 . Male patient ( except prior surgical contraceptive procedure ) female partner childbearing potential : Recommendation male partner use effective contraceptive method , latex condom , study 12 . Able willing provide write informed consent 1 . Preexisting liver disease ( i.e. , cirrhosis , chronic hepatitis B C , nonalcoholic steatohepatitis , sclerosing cholangitis , etc . ) 2 . Active CNS leukemia 3 . Subject concurrent severe and/or uncontrolled medical condition opinion investigator may impair participation study evaluation safety and/or efficacy 4 . NYHA Class IIIIV heart failure , myocardial infarction &lt; 6 month prior study entry , and/or serious arrhythmia require antiarrhythmic therapy 5 . Unable swallow pill 6 . Major surgical procedure within 14 day administration crenolanib ( include line placement need chemotherapy administration ) . 7 . Unwillingness inability comply protocol . 8 . Concurrent use investigational agent . 9 . Subjects eligible standard chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>